Cost-effectiveness of sirolimus therapy with early cyclosporin withdrawal vs. long-term cyclosporin therapy in Australia

Clinical Transplantation

Volumn 20, Issue 4, 2006, Pages 526-536

  Gordois, Adam ^a   Nobes, Michael ^b   Toohey, Michael ^b   Russ, Graeme ^c  

^a M TAG   (Australia)

^b BES (Aust) PL   (Australia)

^c QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

Australia; Benefit analysis; Cost; Cyclosporins; Economics; End stage renal failure; Sirolimus

Indexed keywords

CYCLOSPORIN A; RAPAMYCIN;

AGE DISTRIBUTION; ARTICLE; AUSTRALIA; CLINICAL TRIAL; COCHRANE LIBRARY; COHORT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DATA BASE; DRUG EFFICACY; DRUG SUBSTITUTION; EMBASE; GRAFT SURVIVAL; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEMODIALYSIS; HOSPITAL PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY GRAFT REJECTION; LIFESPAN; LIVER FAILURE; LIVER TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; MEDLINE; META ANALYSIS; NEPHROTOXICITY; OUTPATIENT CARE; POPULATION MODEL; PREDICTION; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; REOPERATION; RESOURCE ALLOCATION; RISK ASSESSMENT; RISK REDUCTION; SENSITIVITY ANALYSIS; STATISTICAL MODEL; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

AUSTRALIA; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; CYCLOSPORINE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MARKOV CHAINS; SIROLIMUS; TRANSPLANTATION IMMUNOLOGY;

EID: 33745684423     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2006.00518.x     Document Type: Article

References (30)

1. Excell L, Chadban S, McDonald S. Transplantation. In: Excell L, McDonald S eds. ANZDATA Registry Report 2004. Adelaide, South Australia: Australia and New Zealand Dialysis and Transplant Registry, 2005: 73. http://www.anzdata.org.au/anzdata/AnzdataReport/download.htm#27thReport [accessed 1 April 2005].
2. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003: 349: 2326.
3. McDonald SP, Russ GR. Associations between use of cyclosporine-sparing agents and outcome in kidney transplant recipients. Kidney Int 2002: 61: 2259.
4. Mihatsch MJ, Kyo M, Morozumi K, Yamaguchi Y, Nickeleit V, Ryffel B. The side-effects of cyclosporine- A and tacrolimus. Clin Nephrol 1998: 49: 356.
5. Morales JM, Wramner L, Kreis H et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002: 2: 436.
6. Citterlo F, Scata MC, Violi P et al. Rapid conversion to sirolimus for chronic progressive deterioration of the renal function in kidney allograft recipients. Transplant Proc 2003: 35: 1292.
7. Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004: 4: 1869.
8. Baboolal K. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (Rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients. Transplantation 2003: 75: 1404.
9. Stallone G, Di Paolo S, Schena A et al. Early withdrawal of cyclosporine A improves 1-yr kidney graft structure and function in sirolimus-treated patients. Transplantation 2003: 75: 998.
10. Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002: 74: 1560.
11. Oberbauer R, Segoloni G, Campistol JM et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005: 18: 22.
12. Oberbauer R, Kreis H, Johnson RW et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-yr results of the Rapamune maintenance regiment. Transplantation 2003: 76: 364.
13. Kreis H, Oberbauer R, Campistol JM et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004: 15: 809.
14. Johnson RWG, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001: 72: 777.
15. Wyeth Pharmaceuticals. Rapamune: 4-year Safety Summary Renal Transplant Recipients in Study. 0468H1-310-GL. Madison, NJ: Wyeth Pharmaceuticals, 2004.
16. Australian Government Department of Health and Ageing. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee. Canberra, Australian Capital Territory: Australian Government Department of Health and Ageing, 2002: 68. http://www7.health.gov.au/pbs/pharm/pubs/guidelines/pdfs/ guidelines.pdf [accessed 13 April 2005].
17. Mota A, Arias M, Taskinen EI et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004: 4: 953.
18. Mathew TH, McDonald SP, Russ GR. Renal transplant outcome beyond 5 years. In: R uss GR ed. ANZDATA Registry Report 2001. Adelaide, South Australia: Australia and New Zealand Dialysis and Transplant Registry, 2002: 105. http://www.anzdata.org.au/anzdata/AnzdataReport/ download.htm#24thReport [accessed 1 April 2005].
19. Excell L, McDonald S (eds). Deaths. In: ANZDATA Registry Report 2004. Adelaide, South Australia: Australia and New Zealand Dialysis and Transplant Registry, 2004: 15. http://www.anzdata.org.au/anzdata/ AnzdataReport/download.htm#27thReport [accessed 1 April 2005].
20. Churchill DN, Torrance GW, Taylor DW et al. Measurement of quality of life in end-stage renal disease: The time trade-off approach. Clin Investig Med 1987: 10: 14.
21. Torrance GW. Utility approach to measuring health-related quality of life. J Chron Dis 1987: 40: 593.
22. McDonald S. Method and location of dialysis. In: Excell L, McDonald S eds. ANZDATA Registry Report 2004. Adelaide, South Australia: Australia and New Zealand Dialysis and Transplant Registry, 2004: 25. http://www.anzdata.org.au/anzdata/AnzdataReport/download.htm-27thReport [accessed 1 April 2005].
23. Australian Government Department of Health and Ageing. Medicare Benefits Schedule 1 November 2004. Canberra, ACT: Australian Government Department of Health and Ageing, 2004. http://www7.health.gov.au/pubs/ mbs/mbsnov04/index.html [accessed 11 April 2005].
24. Australian Government Department of Health and Ageing. Second Revision: Manual of Resource Items and their Associated Costs: Appendix 3. Canberra, ACT: Australian Government Department of Health and Ageing, 2002. http://www.health.gov.au/pbs/pubs/manual/appendix3.htm [accessed 10 September 2003].
25. Australian Institute of Health and Welfare. Health Expenditure Australia 2002-03. Canberra, ACT: Australian Institute of Health and Welfare, 2004: 68. http://www.aihw.gov.au/publications/hwe/hea02-03/hea02-03.pdf [accessed 11 April 2005].
26. Australian Government Department of Health and Ageing. Schedule of Pharmaceutical Benefits Effective from 1 April 2005. Canberra, ACT: Australian Government Department of Health and Ageing, 2005. http://www1.health.gov.au/pbs/index.htm [accessed 11 April 2005].
27. Australian Government Department of Health and Ageing. National Hospital Cost Data Collection: Public Sector Estimated Cost Weights Round 7. Canberra, Australian Capital Territory: Australian Government Department of Health and Ageing, 2004. http://www.health.gov.au/internet/wcms/ Publishing.nsf/Content/health-casemix-costing-fc_r7.htm/$FILE/_R7CWNatEst_Printing%20version.xls [accessed 11 April 2005].
28. Victorian Government Department of Human Services. Renal Dialysis: A Revised Service Model for Victoria. Melbourne, Vic: Victorian Government Department of Human Services, 2005. http://www.health.vic.gov.au/ renaldialysis/renal-finrep-1004.pdf [accessed 12 April 2005].
29. National Health and Medical Research Council. CP73 Toolkit 5: How to Compare the Costs and Benefits: Evaluation of the Economic Evidence. Canberra, ACT: National Health and Medical Research Council, 2002. http://www7.health.gov.au/nhmrc/publications/pdf/cp73.pdf [accessed 5 April 2005].
30. Department of Health and Ageing. Expenditure and Prescriptions Twelve Months to 30 June 2004. Canberra, ACT: Department of Health and Ageing, 2004. http://www.health.gov.au/internet/wcms/publishing.nsf/Content/ health-pbs-general-pubs-pbbexp-jun04.htm/$FILE/bookp01.pdf [accessed 4 May 2005].